New hope for rare, aggressive blood cancer: 3-Drug cocktail targets richter transformation

NCT ID NCT05388006

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that develops from chronic lymphocytic leukemia (CLL). The goal is to control the disease and improve survival. About 27 adults with this condition will receive the treatment to see if it stops cancer growth and helps the immune system fight the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA RICHTER SYNDROME SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••
Stanford Cancer Institute Palo Alto
NOT_YET_RECRUITING

Palo Alto, California, 94304, United States
Washington University School of Medicine
WITHDRAWN

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.